AccuStem Sciences Changes Auditors to BDO USA

TL;DR

AccuStem swapped auditors from CohnReznick to BDO USA, effective April 4th.

AI Summary

AccuStem Sciences Inc. announced on April 4, 2024, that it has appointed a new independent registered public accounting firm, BDO USA, P.A., effective immediately. This change follows the resignation of their previous auditor, CohnReznick LLP, on April 3, 2024. The company has stated that the decision to change auditors was not due to any disagreements with CohnReznick LLP.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors will monitor closely.

Risk Assessment

Risk Level: low — The filing solely concerns a change in the company's auditor and does not involve financial performance or strategic shifts.

Key Players & Entities

• AccuStem Sciences Inc. (company) — Registrant
• BDO USA, P.A. (company) — New independent registered public accounting firm
• CohnReznick LLP (company) — Former independent registered public accounting firm
• April 4, 2024 (date) — Effective date of auditor change
• April 3, 2024 (date) — Date of former auditor's resignation

FAQ

Filing Documents

• form8-k.htm (8-K) — 39KB
• ex16-1.htm (EX-16.1) — 3KB
• 0001493152-24-014171.txt ( ) — 211KB
• acut-20240404.xsd (EX-101.SCH) — 3KB
• acut-20240404_lab.xml (EX-101.LAB) — 33KB
• acut-20240404_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01 Change in Registrant's Certifying Accountant

Item 4.01 Change in Registrant's Certifying Accountant. On April 4, 2024, Accustem Sciences, Inc. (the "Company") was notified that Mazars USA LLP ("Mazars"), the Company's independent registered public accounting firm, will resign as auditor effective with the filing of the Company's Form 10-Q for the quarter ended March 31, 2024 and no later than May 31, 2024. The reports of Mazars on the Company's financial statements for each of fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principle. During the fiscal years ended December 31, 2023 and 2022, there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and Mazars on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures which disagreements, if not resolved to the satisfaction of Mazars would have caused Mazars to make reference thereto in their reports on the financial statements for such years. The Company disclosed in its Form 10-K for the fiscal year ended December 31, 2023, that it did not maintain effective internal control over financial reporting due to a lack of accounting resources and other oversight procedures. The Company provided Mazars with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that Mazars furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements contained herein. A copy of Mazars' letter, dated April 10, 2024 is filed as Exhibit 16.1 to this Current Report on Form 8-K. The Company is in the process of retaining a new independent registered public accounting firm. Item 9.01 Financial Statements and Exhibits (d) Exhibits. The exhibits listed in the following Exhibit Index are filed as par

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ACCUSTEM SCIENCES INC. Date: April 10, 2024 By: /s/ Wendy Blosser Wendy Blosser Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR